Request Legal Help Now - Free


Chantix Increases Risk for Cardiovascular Events, New Study Finds

. By
Washington, DCResults from a new study on the smoking-cessation drug Chantix (varenicline) show that it is associated with a small but significant increase in the risk for cardiovascular events.

The meta-analysis of Chantix studies, published in the online edition of the Canadian Medical Association Journal (CMAJ), found patients who took Chantix experienced more serious cardiovascular events than patients on placebo. While the experts say the difference in the analysis is small, the population effect is not, as some seven million people in the US took Chantix in 2010.

The study, which looked at randomized, placebo-controlled trials involving 8,216 people, follows on from a revision of the prescribing information for Chantix, as stated by the Food and Drug Administration in June, to include a warning about an increased risk for second heart attack and peripheral artery disease in people who have a history of cardiovascular disease.


Chantix Legal Help

If you or a loved one have suffered losses in this case, please click the link below and your complaint will be sent to a drugs & medical lawyer who may evaluate your claim at no cost or obligation.


Fields marked * are mandatory. Please read our comment guidelines before posting.


Note: Your name will be published with your comment.

*Email Address:

Your email will only be used if a response is needed.
*Your Comment:

Are you the defendant or a subject matter expert on this topic with an opposing viewpoint? We'd love to hear your comments here as well, or if you'd like to contact us for an interview please submit your details here.

Click to learn more about

Request Legal Help Now! - Free